XML 45 R24.htm IDEA: XBRL DOCUMENT v3.20.1
Organization and Significant Accounting Policies - Additional Information (Detail)
1 Months Ended 6 Months Ended
Oct. 03, 2018
USD ($)
Target
Sep. 28, 2016
USD ($)
Dec. 31, 2019
USD ($)
Mar. 31, 2020
USD ($)
Mar. 31, 2019
USD ($)
Sep. 30, 2019
USD ($)
Organization And Significant Accounting Policies [Line Items]            
Proceeds from the issuance of common stock     $ 250,500,000 $ 250,478,974 $ 60,521,729  
Cash and cash equivalents       256,650,727   $ 221,804,128
Restricted Cash       1,800,000    
Short term investments       50,959,058   36,899,894
Long term investments       190,618,075   $ 44,175,993
Net increase (decrease) in cash and investments       195,400,000    
Right-of-use assets       10,263,197    
Right-of-use liabilities       14,867,189    
Janssen | JNJ-3989 (ARO-HBV) Agreement            
Organization And Significant Accounting Policies [Line Items]            
Milestone payment $ 25,000,000     25,000,000    
Janssen | Collaboration Agreement            
Organization And Significant Accounting Policies [Line Items]            
Number of additional targets for development and sales milestone payments | Target 3          
Janssen and JJDC | Collaboration and License agreements            
Organization And Significant Accounting Policies [Line Items]            
Cash received as due under agreement $ 175,000,000          
JJDC | Common Stock Purchase Agreement            
Organization And Significant Accounting Policies [Line Items]            
Proceeds from the issuance of common stock 75,000,000          
Amgen | License Collaboration and Stock Purchase Agreement            
Organization And Significant Accounting Policies [Line Items]            
Cash received as due under agreement   $ 35,000,000        
Proceeds from the issuance of common stock   21,500,000        
Amgen | AMG-890 (ARO-LPA) Agreement            
Organization And Significant Accounting Policies [Line Items]            
Milestone payment   $ 10,000,000        
Maximum | Janssen | License Agreement            
Organization And Significant Accounting Policies [Line Items]            
Development regulatory and sales milestones payments 1,600,000,000          
Maximum | Janssen | Collaboration Agreement            
Organization And Significant Accounting Policies [Line Items]            
Development regulatory and sales milestones payments $ 1,900,000,000          
Maximum | Amgen | AMG-890 (ARO-LPA) Agreement            
Organization And Significant Accounting Policies [Line Items]            
Development regulatory and sales milestones payments       $ 420,000,000